# Damora Therapeutics, Inc.

**DMRA**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001800315


# None

**No letter**

6 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $260.5M |
| **Warnings** | dilution, thin data, distress<br>not computable: degenerate inputs, fortress balance sheet |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Mar 19, 2026<br>236 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026 |
| **Last close** | $24.07<br>2026-11-09; market equity $1.5B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 19, 2026*

We are a biopharmaceutical company developing therapies for the treatment of hematologic disorders. In our previously announced Asset Acquisition (as defined below), we bolstered our pipeline with the addition of three product candidates designed to treat myeloproliferative neoplasms ("MPNs"), a group of related, chronic disorders of the bone marrow. Our lead product candidate, DMR-001, targets mutant forms of the calcium binding protein calreticulin ("CALR"), which are collectively known as mutCALR. We have exercised our Option to license exclusive worldwide development and commercialization rights to DMR-001 from Paragon Therapeutics, Inc.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 3.1** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (146.3%) | (6.6%) | | 3.1 | 800 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 37.2** | | | | | | |
| Twelve-month failure probability | 1.56% | 0.08% | | 87.4 | 248 | 2026-09-30 |
| Altman Z double-prime | 7.04 | (0.35) | | 14.1 | 745 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 12.98x | 2.95x | | 10.1 | 826 | 2025-12-31 |
| **Growth and financing, sleeve percentile 52.8** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four annual observations are required; found 0* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | | |
| *four consecutive annual FCF observations are required; found 2* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | 52.7% | 2.2% | | 7.2 | 694 | 2025-12-31 |
| Net share issuance, one year | 4,460.3% | 2.5% | | 98.4 | 629 | 2026-03-17 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 4460.3% |
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |
| Distress | CHS probability 1.558639%; universe top-decile threshold 1.400994% |

## What the price implies

*at the 2026-11-09 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 190.7% | (1.9%) | 95 |
| Distance from 52-week high | (29.5%) | (27.5%) | 48 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (2.9%) | (1.0%) | 45 |
| Book value to price | 0.33 | 0.27 | 56 |
| Sales to price | not computable | 0.29 | |
| Composite equity issuance, five years | 411.5% | 20.8% | 97 |
| Relative strength against the sector, log excess return | 0.90 | (0.19) | 95 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |

**Cash, filings, liquidity**

| | |
|---|---|
| Cash and equivalents | $349.7M |
| Operating cash flow, four quarters | -$59.1M |
| Months of runway | 71.0 |
| Days since last periodic filing | 6 (10-Q received Nov 4, 2026) |
| Median daily dollar volume, 63 sessions | $10.4M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$209.8M | 2025-12-31 | 2026-03-19 | 10-K | 26-115922 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$6.7M | 2025-12-31 | 2026-03-19 | 10-K | 26-115922 |
| 3 | assets | us-gaap:Assets | $260.5M | 2025-12-31 | 2026-03-19 | 10-K | 26-115922 |
| 4 | assets | us-gaap:Assets | $17.1M | 2024-12-31 | 2026-03-19 | 10-K | 26-115922 |
| 5 | current assets | us-gaap:AssetsCurrent | $260.4M | 2025-12-31 | 2026-03-19 | 10-K | 26-115922 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $20.1M | 2025-12-31 | 2026-03-19 | 10-K | 26-115922 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$487.4M | 2025-12-31 | 2026-03-19 | 10-K | 26-115922 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$210.9M | 2025-12-31 | 2026-03-19 | 10-K | 26-115922 |
| 9 | book equity | us-gaap:StockholdersEquity | $240.4M | 2025-12-31 | 2026-03-19 | 10-K | 26-115922 |
| 10 | liabilities | us-gaap:Liabilities | $20.1M | 2025-12-31 | 2026-03-19 | 10-K | 26-115922 |
| 11 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $196,000 | 2022-12-31 | 2024-03-08 | 10-K | 24-028610 |
| 12 | depreciation amortization | us-gaap:Depreciation | $42,000 | 2022-12-31 | 2024-03-08 | 10-K | 24-028610 |
| 13 | operating income | us-gaap:OperatingIncomeLoss | -$61.2M | 2022-12-31 | 2024-03-08 | 10-K | 24-028610 |
| 14 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$61.6M | 2022-12-31 | 2024-03-08 | 10-K | 24-028610 |
| 15 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2022-12-31 | 2024-03-08 | 10-K | 24-028610 |
| 16 | current assets | us-gaap:AssetsCurrent | $63.9M | 2022-12-31 | 2024-03-08 | 10-K | 24-028610 |
| 17 | current liabilities | us-gaap:LiabilitiesCurrent | $11.1M | 2022-12-31 | 2024-03-08 | 10-K | 24-028610 |
| 18 | current assets | us-gaap:AssetsCurrent | $110.1M | 2021-12-31 | 2023-03-09 | 10-K | 23-006807 |
| 19 | current liabilities | us-gaap:LiabilitiesCurrent | $4.5M | 2021-12-31 | 2023-03-09 | 10-K | 23-006807 |
| 20 | assets | us-gaap:Assets | $38.2M | 2023-12-31 | 2025-03-19 | 10-K | 25-041981 |
| 21 | assets | us-gaap:Assets | $73.2M | 2022-12-31 | 2024-03-08 | 10-K | 24-028610 |
| 22 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 60,303,212 | 2026-03-17 | 2026-03-19 | 10-K | 26-115922 |
| 23 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 1,322,359 | 2025-03-14 | 2025-03-19 | 10-K | 25-041981 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.